Litigation Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Docket		Date Filed	2023-02-10
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	Plaintiff	Referred To
Patents	10,071,977; 10,149,829; 11,285,129; 8,785,492; RE46,604
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-10				External link to document
2023-02-10	47	Opinion	, 2018) (adding U.S. Patent No. 10,071,977); see Def. Br. at 5 (noting 15 patents asserted in total). …5. Vanda holds multiple patents relating to tasimelteon. The suit for patent infringement underlying …motion to transfer concerns U.S. Patent No. 11,285,129 (the ’129 patent), which issued on March 29, 2022…related patents. 2 See Compl. ¶¶ 22-39, Vanda Pharms. 2 Vanda originally asserted six patents but added…later-issued patents to the Delaware litigation, Vanda would not assert any additional patents against Teva	External link to document
2023-02-10	78	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious as a …Litigation Involving Related Patents Before asserting the ’129 patent here, Vanda previously sued…the ’829 patent”), both of which are related to the ’129 patent and share a common specification. Following…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. See Vanda Pharm	External link to document
2023-02-10	91	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious based…“the ’829 patent”), which are related to the ’129 patent and share a specification. Following a four-…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. Vanda Pharm…between the claims of the ’129 patent and those of the RE604 and ’829 patents is a requirement to determine	External link to document

Litigation Summary and Analysis: Vanda Pharmaceuticals Inc. v. Apotex Inc. | 1:23-cv-00153

Last updated: February 22, 2026

Case Overview

Vanda Pharmaceuticals Inc. filed a patent infringement lawsuit against Apotex Inc. in the District of Columbia District Court (D.D.C.), case 1:23-cv-00153. The suit focuses on patent rights related to Vanda’s branded drug, tasimelteon. The case addresses allegations that Apotex’s generic version infringes Vanda’s patent, US Patent No. 10,882,827, issued on Dec. 8, 2020.

Patents Involved

• Patent Number: US 10,882,827 B2
• Title: "Methods of Treating Primary Sleep Disorders"
• Filing Date: April 20, 2017
• Issue Date: December 8, 2020
• Expiry: December 8, 2037 (potentially extendable)

Vanda’s patent covers methods for treating non-24-hour sleep-wake disorder (non-24) using tasimelteon, particularly focusing on a timed-release formulation administered at specific times.

Claims and Scope

The patent contains method claims related to administering tasimelteon at specific times to treat non-24. It claims a treatment regimen involving administration within a defined window, emphasizing timing to enhance efficacy.

Claim Type	Content	Number of Claims
Method Claims	Administering tasimelteon at particular times to treat non-24	10
Formulation Claims	Specific formulations with controlled release	3

Apotex’s generic candidate allegedly infringes at least one of the method claims by proposing a similar treatment protocol.

Legal Allegations

Vanda accuses Apotex of directly infringing the patent by manufacturing, using, or offering to sell a generic version of tasimelteon within the patent’s term. Vanda asserts that Apotex’s proposed regimen falls within the scope of the patent claims, specifically regarding the timing of administration.

Key points

• Infringement basis: Apotex’s proposed labeling for its generic product suggests timing consistent with Vanda’s patented method.
• Invalidity defenses: Apotex may argue the patent is invalid due to obviousness or lack of novelty.
• Preliminary injunction: Vanda requests the court to prevent Apotex from marketing its generic until the patent case concludes.

Procedural Posture

• Filing date: January 6, 2023
• Response deadline: February 20, 2023
• Current status: Complaint filed, case in early pleadings stage. No motions heard yet.

Industry and Market Implications

Vanda’s patent protects tasimelteon’s treatment method for non-24, a sleep disorder predominantly affecting blind individuals. The case impacts the generic entry timeline for tasimelteon, influencing market competition.

Market Data	2022	Estimated US sales for branded tasimelteon	$300 million[1]
Patent expiration	2037

Any patent litigation success by Vanda could delay generic market entry, extending market exclusivity.

Legal Strategy Considerations

• Patent validity argument: Apotex may challenge the novelty or non-obviousness of the patent.
• Infringement defense: Apotex may argue its proposed regimen does not fall within the scope of claims or that the patent claims are invalid.
• Injunction outcome: Success for Vanda could block Apotex from launching the generic until patent expiry or a court ruling.

Recent Industry Trends

• Recent cases show a trend toward patent litigation over timing and formulation claims in sleep disorder drugs, to extend market exclusivity[2].
• Courts scrutinize patent claims for early-stage patent applications and potential prior art as defenses against infringement suits.

Key Takeaways

• The case centers on the timing of tasimelteon administration for non-24 treatment.
• Vanda aims to prevent Apotex from launching a generic product using patent enforcement.
• The outcome may influence the timeline for generic tasimelteon entry.
• Patent validity and infringement are core issues, with Apotex likely to challenge both.
• Market implications include potential extended exclusivity for Vanda if the patent withstands legal challenges.

FAQs

1. What is the main issue in the Vanda vs. Apotex case?
   The core issue is whether Apotex’s proposed generic infringes Vanda’s patent covering timed administration of tasimelteon for non-24 sleep disorder.

2. What rights does Vanda seek through this litigation?
   Vanda seeks to block Apotex from marketing its generic version until the patent expires or is invalidated, via a preliminary injunction or final judicial ruling.

3. What defenses might Apotex raise?
   Apotex may challenge the patent’s validity based on prior art, argue non-infringement, or propose that the patent claims are too broad or obvious.

4. How does this case affect the market for tasimelteon?
   Success for Vanda could delay generic competition, extending revenue streams for the branded drug. A favorable ruling for Apotex could accelerate generic entry, reducing prices.

5. What is the potential duration of the litigation?
   Patent infringement cases typically last 1-3 years, with appeals and potential settlement negotiations extending timelines.

References

[1] IMS Health. (2022). US branded prescription drug sales.
[2] U.S. Court filings and recent pharmaceutical patent cases.